Recent Research

Miklos DB, et al.- Novel research published in the Journal of Clinical Oncology investigated the effectiveness of ibrutinib as a first-line treatment for newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD) in patients without prior systemic treatment. While the results did not show statistical significance in response rates, duration of response, and overall survival, the study emphasized the urgent need for more effective cGVHD treatments and research in this vital area.

Liberio N, et al. – The CIBMTR conducted a study to address the lack of data guiding haploidentical (haplo) donor selection for pediatric HCT. Research presented at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting showed that sibling donors had a lower risk of acute and chronic graft-versus-host disease and graft failure when compared to parental donors. The study suggests sibling donors may be the optimal haplo donor choice for pediatric HCT to minimize risks and improve outcomes.

Bolaños-Meade J, et al., The Lancet Haematology – In a prospective, phase II trial, researchers found that tacrolimus, mycophenolate mofetil, with post-hematopoietic cell transplant (HCT) cyclophosphamide (TMMCy) produced the best GVHD-free, relapse-free survival (GRFS) for patients who received an allogeneic HCT when compared to the current standard of care.

Zeiser R, et al. Blood – The latest research in cellular therapies, antibody-based treatments, and tyrosine kinase inhibitor (TKI)-based approaches to enhance GVL effects are outlined in articles published in a special edition of Blood.